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Abstract
Introduction: Tyrosine phosphorylated signal transducer and activator of transcription 3 (pStat3) is expressed in
numerous cancers and is required for mediating tumorigenesis. Autocrine and paracrine interleukin (IL)-6 signaling
is the principal mechanism by which Stat3 is persistently phosphorylated in epithelial tumors including breast,
lung, colon and gastric cancer. The Ras oncogene mediates cellular transformation without evidence of pStat3 in
cultured cells. However, non-tyrosine phosphorylated Stat3 was shown to function as a transcriptional activator,
localize to the mitochondria and regulate ATP synthesis and mediate cell migration. Here we examined the role of
Stat3 in Ras mediated transformation.
Methods: Ha-rasV12 transformed mammary epithelial cells (MCF10A-Ras) cells were transduced with a Stat3shRNA,
IL-6shRNA and/or treated with inhibitors of Janus kinases (JAKs) to examine the role of the IL-6 signaling pathway
in Ras mediated migration, invasion and tumorigenesis.
Results: Cellular migration, invasion, anchorage independent growth and tumorigenesis were largely abrogated in
the Stat3-reduced cells compared to control cells. Analysis of MCF10A-Ras tumors revealed high levels of pStat3
and interleukin-6. Tumors derived from transgenic MMTV-K-Ras mice were also found to express pStat3 and IL-6.
MCF10A-Ras cells, when grown in a three-dimensional Matrigel culture system revealed the appearance of the
junctional protein E-Cadherin as a consequence of reducing Stat3 levels or inhibiting Stat3 activity. Decreasing IL-6
levels in the MCF10A-Ras cells abrogated tumorigenesis and reduced cell migration. By isolating Ras-expressing
primary tumors and serially passaging these cells in two-dimensional culture led to a decrease in IL-6 and pStat3
levels with the reappearance of E-Cadherin.
Conclusions: The cellular and environmental context can lead to differential IL-6/pStat3 signaling and a
dependency on this cytokine and transcription factor for migration, invasion and tumorigenesis.
Introduction
The Signal transducers and activators of transcription
(Stat) family of proteins are transcription factors known
for their role as integrators of cytokine and growth fac-
tor receptor signaling and are required for cell growth,
survival, differentiation, and motility [1,2]. Stat activation
is dependent upon tyrosine phosphorylation, which
induces dimerization via reciprocal phosphotyrosine-src
homology domain 2 (phosphotyrosine-SH2) interaction
between two Stat molecules. Activated Stat’st r a n s l o c a t e
to the nucleus where they bind to consensus promoter
sequences of target genes and activate their transcrip-
tion [3]. In normal cells, Stat tyrosine phosphorylation is
transient. However, in numerous cancer-derived cell
lines and in an ever growing number of primary tumors,
Stat proteins (in particular Stat3) are persistently tyro-
sine phosphorylated [4]. Stat3 is found to be constitu-
tively phosphorylated to high levels in >50% of breast
cancer derived cell lines and in >30% of breast adeno-
carcinomas and may be a poor prognostic indicator
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any medium, provided the original work is properly cited.[5,6]. Constitutive activation of Stat3 in epithelial can-
cers and cancer derived cell lines is frequently due to
aberrant autocrine or paracrine IL-6 signaling [7]. Inhi-
bition of Stat3 activity in tumor-derived cell lines both
in vitro and in vivo, by the introduction of antisense,
small interfering RNA, decoy molecules, dominant-
negative Stat3 constructs, and/or blockade of tyrosine
kinases has been associated with growth arrest, apopto-
sis, decreased angiogenesis and invasion [2,4,8,9]. More
recently, non-canonical functions for Stat3 have been
identified including non-tyrosine phosphorylated Stat3
mediating transcriptional activation, non-tyrosine
phosphorylated Stat3 binding to stathmin a microtubule
associated protein and regulating migration, non-
tyrosine phosphorylated Stat3 regulating metabolic func-
tions in the mitochondria leading to Ras-dependent
transformation [10-12].
The ras proto-oncogene encodes a guanine nucleotide
binding protein that plays an essential role in diverse cel-
lular responses, including cell proliferation and differen-
tiation [13]. Although ras mutations are infrequent in
human breast cancers, elevated amounts of the ras pro-
tein have been found in 60 to 70% of human primary
breast carcinomas [14]. Ras expression has been sug-
gested to be a marker of tumor aggressiveness in breast
cancer, including the degree of invasion into fat tissue,
infiltration into lymphatic vessels and tumor recurrence
[14-16]. Rodent fibroblasts and human mammary epithe-
lial cell lines transformed by the H-Ras oncogene do not
express tyrosine phosphorylated Stat3 [17-19]. Moreover,
non-tyrosine phosphorylated Stat3 was demonstrated to
regulate metabolic functions in the mitochondria leading
to Ras-dependent transformation [20].
Here we further investigated the role of non-tyrosine
phosphorylated Stat3 in Ras-mediated mammary tumor-
igenesis. Specifically, we examined the consequences of
reducing Stat3 levels in Ras transformed mammary
epithelial cells. We determined that Stat3 deficient Ras
transformed MCF10A cells were less capable of mediat-
ing migration, invasion and tumorigenesis than the con-
trol MCF10A-Ras cells. Surprisingly, tumors derived
from MCF10A-Ras cells expressed high levels of tyro-
sine phosphorylated Stat 3 (pStat3) as did mammary
tumors from MMTV-expressing K-Ras mice. Further-
more, the interleukin-6 ligand (IL-6) which was recently
shown to be a principal regulator of Stat3 activation in
breast cancer [6], was found to be elevated in both
MCF10A-Ras and MMTV-K-Ras tumors. In addition,
growth of MCF10A-Ras cells in the presence of base-
ment membrane proteins (Matrigel) resulted in high
levels of pStat3. Reduction of Stat3 levels or inhibition
of its activity led to the up-regulation of E-cadherin in
MCF10A-Ras cells. We demonstrated that culturing and
passaging primary Ras-expressing tumors from 3-D to
2-D resulted in a diminution of pStat3 and IL-6 levels
suggesting that depending on the context in which
MCF10A-Ras expressing cells are grown can signifi-
cantly alter the levels of pStat3 and the subsequent
behavior of the cells.
Materials and methods
Plasmids, protein extraction, Western blot analysis, EMSA
and RNA analysis
The pBabe-H-RasV12 construct was a gift from P. Sicinski
(Dana-Farber Cancer Institute) [21]. Stat3shRNA lentiviral
and scrambled control shRNA constructs were previously
described [22]. The pSuper-Il-6 shRNA-GFP retroviral
construct was generated by substituting PKG-puro with
CMV-GFP. pSuper IL-6 shRNA was a gift from C. Coun-
ter [23]. Nuclear and cytoplasmic extracts were prepared
as previously described [24]. Radioimmunoprecipitation
assay (RIPA) buffer extracts were utilized in the protein
extraction of all tissues and Western blots were carried
out as previously described [25]. Protein concentrations
were determined using the Bradford assay (BioRad,
Hercules, CA, USA). EMSAs were carried out as pre-
viously described [26] by using a radiolabeled high-affinity
m67 DNA binding probe and an anti-Stat3 antibody for
supershifting (Stat3 (K-15): sc-483 X, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). RNA was isolated using
t h eR N e a s yk i t( Q I A G E N ,V a l e n c i a ,C A ,U S A ) .T w o
micrograms of total RNA was used for IL-6 and b-actin
RT-PCR using an iScript RT-PCR kit (Bio-Rad) according
to the manufacturer’s instructions. Sequences of primers
for amplification of the IL-6 gene were as follows: forward
primer, 5’-TAGCCGCCCCACACAGACAG-3’; reverse pri-
mer, 5’-GGCTGGCATTTGTGGTTGGG-3’.T h eb-actin
primers were as follows: forward primer, 5’-CGT
GCGTGACATTAAGGAGA-3’; reverse primer, 5’-TGATC-
CACATCTGCTGGAAG-3’. For quantitative PCR 1 ug of
total RNA was reverse-transcribed using the Thermoscript
RT-PCR system (Invitrogen) at 52°C for one hour. 20 ng
of resultant cDNA was used in a Q-PCR reaction using an
iCycler (Biorad) and pre-designed TaqMan ABI Gene
expression Assays (Hs00985639_m1 for IL-6). Amplifica-
tion was carried for 40 cycles (95°C for 15 seconds, 60°C
for 1 minute). To calculate the efficiency of the PCR reac-
tion, and to assess the sensitivity of the assay, we also per-
formed a seven-point standard curve (5, 1.7, 0.56, 0.19,
0.062, 0.021, and 0.0069 ng). To obtain normalized
qPCR values for IL-6, triplicate cycle threshold values
were averaged, amounts of target were interpolated from
the standard curves and normalized to HPRT (hypox-
anthine guanine phosphoribosyl transferase, assay
Hs99999909_m1). Antibodies used were: anti-tubulin
monoclonal antibody (1:2500) (Sigma, St. Louis, MO,
USA); Anti-H-Ras polyclonal antibody (1:1000) (Santa
Cruz Biotechnology); Anti-Stat 3 and anti-Tyr 705 Stat3
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MA, USA) and Anti-E-cadherin monoclonal antibody
(1:1000) (Zymed Laboratories, San Francisco, CA, USA).
Cell culture, growth curves, retroviral/lentiviral infections
MCF10A and 293T cells were obtained from the Ameri-
can Type Culture Collection. MCF10A cells were cul-
tured as previously described [27]. 293T cells were
grown in Dulbecco’s modified Eagle medium (DMEM)
containing 10% Cosmic Calf serum (Hyclone, Logan,
UT, USA). Cells were plated on plastic coated Matrigel,
Fibronectin, Laminin, CollagenI, CollagenV (BD Bios-
ciences). Human IL-6 was used at 10 ng/ml (R&D Sys-
tems, Minneapolis, MN, USA). To measure cell growth,
2×1 0
4 cells per well (2 × 10
3/cm
2)w e r ep l a t e di n t o
six-well dishes. Cells were counted at Days 1, 2, 3, 4, 5
and 6. Each data point represents the mean value from
triplicate wells. All transfections were carried out using
Superfect (QIAGEN). Retroviral infections were carried
out using the RetroMax Retroviral Expression System
pCL-Ampho (Imgenex, San Diego, CA, USA) according
to the supplier. Clonal selection was carried out using
puromycin (2 ug/ml) (Sigma). Lentiviral infections were
performed using lentivirus-based vectors encoding
shRNA IRES eGFP targeted to either Stat3 or IL-6 tran-
scripts, and were generated by transient co-transfection
of 293T cells with a three-plasmid combination, as
described previously [28]. EGFP expressing cell popula-
tions positive for each shRNA were sorted by FACS.
Migration/invasion
Migration/invasion experiments were performed as
described previously [29,30]. Briefly, cells (5 × 10
4) were
starved for 16 hours in media lacking EGF and were
subsequently applied to an 8-μm pore cell culture
inserts or in Matrigel Invasion Chambers (Falcon/BD
Labware, Franklin Lakes, NJ, USA). MCF10A media
containing 2% horse serum and EGF was used as the
chemoattractant with or without IL-6 (10 ng/ml). After
16 h of incubation, the cells were stained with crystal
violet and counted. Each condition was assayed in tripli-
cate, experiments were performed independently at least
three times, and the results were expressed as the num-
ber of cells per field.
Morphogenesis assay
Morphogenesis assays were carried out as previously
described [27]. Growth Factor Reduced Matrigel was
obtained from BD Biosciences (BD No.354230). For
inhibitor incubation, the following concentrations of
i n h i b i t o ro ra n t i b o d yw e r eu s e d :1μM P6 (Calbiochem,
San Diego, CA, USA), 10 μg/mL BR3 (Diaclone, Stam-
ford, CT, USA) and 2 μg/mL anti-IL-6 522 (Cell
Sciences, Conton, MA, USA). Antibodies for staining of
acini were as follows: anti-phospho Stat3 # 9135, 1:50
(Cell Signaling); anti-E-Cadherin 1:200 (Zymed Labora-
tories). Examination of the staining of cells was carried
out using a Leica inverted confocal microscope.
Soft agar assay/tumor growth
Anchorage-independent growth in triplicate was
assessed as previously described [17]. Cells (4 × 104) in
4 ml of a 0.35% agar-MCF10A media solution were pla-
ted in triplicate on 35-mm-diameter dishes containing a
0.7% agar plug (BiTek, DIFCO Laboratories, Detroit, MI,
USA). Colonies were stained with 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) and
counted after three weeks. Cells (107) were harvested
and mixed with an equal volume of Matrigel (Becton
D i c k i n s o nL a b w a r e ,B e d f o r d ,M A ,U S A ) ,a n d2 0 0 - μl
doses were injected into the flanks of six- to eight-week-
old male NCr athymic nude mice (NCI, Frederick, MD,
USA). Tumor sizes were measured after four weeks and
tumor volume was calculated using the formula length
× width × depth × 1/2. Each cell line was injected in a
minimum of five animals.
Isolation of extracts and cell lines from tumors: MMTV-
KRas tumors and MCF10A Ras
Mammary tumors from MMTV-KRas mice and xeno-
graft MCF10A-Ras tumors were dissected [31]. Half of
the tumors were frozen in liquid nitrogen, and ground
to a powder for RNA and protein analysis. The remain-
ing tumors were mechanically dissociated with scalpels
and enzymatically digested in a) DMEM: F-12 with 1
mM glutamine, 5 μg/ml insulin, 500 ng/ml hydrocorti-
sone, 10 ng/ml epidermal growth factor, 20 ng/ml cho-
lera toxin, 5% horse serum, 300 U/ml collagenase and
100 U/ml hyaluronidase (Sigma) for one hour at 370C
followed by 0.1 mg/mL DNase treatment (Worthington,
Lakewood, NJ, USA) for one minute subsequently
washed in DMEM with 10% FBS and resuspended and
plated in MEGM media (Cambrex, Walkersville, MD,
USA) (for MMTV-KRas tumors) b) 0.25% trypsin for 5’
at 37°C followed by washing in DMEM with 10% FBS
and plated in MEGM media (for MCF10A Ras tumors).
Cells were plated and subcultured daily. Supernatants
were saved for IL-6 ELISA’s, and RIPA extracts were
made for protein analysis. ELISA analysis for human
and murine IL-6 was performed using the manufac-
turer’s instructions (Cell Sciences).
Immunofluoresence and Immunohistochemistry
Tumors were fixed in 4% paraformaldehyde and embedded
in paraffin. Tissue sections were stained for IL-6 using
anti-IL-6 (1:200; Abcam, Cambridge, MA, USA) using pre-
viously described methods [32]. Imaging was carried out
on a Leica Inverted Confocal Microscope.
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Data are expressed as means ± standard deviation (SD).
The statistical significance of differences was evaluated
using an unpaired, non-parametric Student’s t-test. Sig-
nificant differences between experimental groups were
* P < 0.05 or ** P < 0.01.
Results
Stat3 is required for Ras-mediated migration, invasion
and tumorigenesis of human mammary epithelial cells
We examined the role of Stat3 in H-RasV12 mediated
cell migration, invasion and cellular transformation
using H-RasV12 transformed mammary epithelial cells
(MCF10A-Ras). MCF10A cells are a spontaneously
immortalized human breast epithelial cell line, mutant
in the cdk inhibitor p16, yet has many of the character-
istics of normal breast epithelium, do not form tumors
in nude mice nor form colonies in soft agar, but
undergo transformation upon the introduction of
Ha-Ras [33-35]. The H-RasV12 oncogene was intro-
duced into MCF10A cells by retroviral gene transfer,
and Ras expressing cells were selected in puromycin
containing media. A Stat3sh or scrambled control
shRNA-GFP constructs were introduced into H-RasV12
transformed MCF10A cells by lentiviral infection and
sorted for GFP expression (Stat3sh and control lines
respectively). Tyrosine phosphorylated Stat3 was unde-
tectable in the MCF10A-Ras cells (Figure 1a). Stat3sh
expressing cells displayed lower levels of total Stat3 pro-
tein by Western blot analysis and Ras protein levels
were constant (Figure 1a). The morphology and growth
rates of the Stat3sh cells were similar to control cells, as
were their requirements for defined media components
including EGF (Figure 1b and data not shown).
Ras transformed cells have increased invasive and
migratory potential over control non-transformed cells
[36]. We investigated whether Stat3 may be required for
this phenotype and compared Stat3sh to control cells
(Figure 1c). The Stat3sh expressing cells displayed an
approximately four-fold decrease in migration in a Boy-
den chamber assay, compared to control cells (Figure
1c). Additionally, we observed a nearly 10-fold reduction
in invasion through a matrigel coated insert in the
Stat3sh cells compared with controls. Hence, Stat3 is a
modulator of the invasive and migratory potential of Ras
transformed mammary epithelial cells.
The finding that Stat3 is required for invasion and
migration in Ras transformed MCF10A cells led us to
determine if Stat3 might also be required for tumorigen-
esis. Anchorage-independent-growth is a measure of a
cells capacity to grow in three dimensions, without con-
tacting a basement membrane. We next determined
whether Stat3 expression affects anchorage independent
growth of MCF10A-Ras cells. Control cells displayed
Figure 1 Stat3 is required for the migratory, invasive and
tumorigenic phenotype of Ras transformed MCF10A cells. (a)
Extracts from Ras transformed MCF10A cells (MCF10A-Ras)
expressing control (C) or Stat3 shRNA (S3sh) were analyzed for
levels of Stat3, tyrosine phosphorylated (pStat3), Ras and Tubulin by
Western blot analysis. (b) MCF10A-Ras cells expressing control (C) or
Stat3 shRNA (S3sh) were plated in six-well dishes and cell numbers
were determined daily for seven days. Each data point represents
the mean value from triplicate wells. (c) MCF10A-Ras cells
expressing control (C) or Stat3 shRNA (S3sh) were plated into
Boyden chambers and cell migration (MIG) and invasion (INV) was
determined with crystal violet staining after 24 hrs. Results are
expressed as cells/field (mean ± SD of triplicates from three
independent experiments). (d) Colony formation in soft agar of
MCF10A-Ras cells expressing control (C) or Stat3 shRNA (S3sh)
(mean ± SD of triplicates from three independent experiments).
Tumor growth in nude mice using MCF10A-Ras cells expressing
control (C) or Stat3 shRNA (S3sh) was determined (mean ± SD from
four independent injections).
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few colonies (approximately 10-fold less) (Figure 1d).
Tumorigenesis was determined by injecting both control
and Stat3sh cells into nude (nu/nu athymic) mice. Mice
injected with Stat3sh cells formed tiny acellular tumors
(0.007 cm3) relative to control cells (0.412 cm3) (Figure
1d). Taken together, these results indicate that Stat3 is
required for Ras mediated transformation of MCF10A
cells.
Ras expressing mammary tumors exhibit high levels of
activated Stat3 and IL-6
We next examined the levels of pStat3 in these tumors
by immunohistochemical and Western blot analyses.
Surprisingly, we observed high pStat3 levels in the con-
trol tumors (both tumor cells and adjacent stromal
cells), while the Stat3sh tumors had very low levels of
pStat3 (Figure 2a). The cells expressing pStat3 and total
Stat3 within the Stat3sh tumors were principally non-
tumor cells (Figure 2a). We recently showed that a prin-
cipal mechanism of Stat3 activation in breast and lung
cancers is through autocrine production of IL-6 [6,32].
Furthermore, it was shown that a number of Ras trans-
formed cells express high levels of IL-6 which promotes
angiogenesis and tumorigenesis [23]. We therefore ana-
lyzed these tumor samples for IL-6 expression by immu-
nohistochemistry and determined that control tumors
expressed high levels of IL-6 (Figure 2a). To demon-
strate that our observations were not specific to the
MCF10A-Ras cell line, we examined mice expressing the
K-Ras oncogene within the mammary gland (MMTV-
K-Ras). These tumors also expressed high levels of
pStat3 (by immunohistochemistry and Western blot
analysis) and IL-6 (by immunofluoresence) (Figure 2b).
Paracrine IL-6 enhances autocrine IL-6/pStat3 signaling
and migration in MCF-10A-Ras cells
It was recently determined that exogenous sources of
IL-6 could enhance autocrine production of IL-6 in
models of breast cancer where IL-6/pStat3 levels were
very low [37]. Furthermore, IL-6 has been shown to pro-
mote an epithelial-mesenchymal transition in breast
cancer which correlated with enhanced invasion [38].
Given our observation that MCF10A-Ras cells express
IL-6 and pStat3 in 3-D, we wished to determine whether
exogenous IL-6 could lead to Stat3 phosphoryaltion and
inducible expression of endogenous IL-6 in MCF10A-
Ras cells grown in 2-D. We treated cells with IL-6 and
observed a marked increase in pStat3 levels by Western
blot analysis, Stat3 DNA binding activity by electrophor-
ectic mobility shift assay (EMSA) as well as IL-6 mRNA
levels (Figure 3a, b, c). We also examined the effect of
exogenous IL-6 on MCF10A-Ras cell migration and
determined that IL-6 enhanced MCF10A-Ras cell
Figure 2 Ras expressing mammary tumors exhibit high levels
of activated Stat3 and IL-6. (a) Paraffin embedded tumors from
MCF10A-Ras cells expressing control (Ras-C) or Stat3shRNA (RasS3sh)
were examined by hematoxyline and eosin (H&E), pStat3 and IL-6
by immunohistochemistry. Extracts from MCF10A-Ras expressing
control (C) or Stat3 shRNA (S3sh) tumors were analyzed for pStat3
and Tubulin by Western blot analysis. (b) Paraffin embedded tumors
from MMTV-promoter driven K-Ras (MMTV-K-Ras) were analyzed by
hematoxyline and eosin stain (H&E), for pStat3 by
immunohistochemistry and for IL-6 by immunofluorescence. Extracts
from normal mammary tissue (N) or MMTV-K-Ras (K-Ras) were
analyzed for pStat3, Stat3 and Tubulin.
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not promote migration in RasS3Sh cells (Figure 3d).
Thus, paracrine or exogenous sources of IL-6 enhances
pStat3 levels, Stat3 binding activity and cell migration in
a Stat3 dependent manner.
MCF10A-Ras cells grown in Matrigel express IL-6 and
pStat3 which regulate E-Cadherin levels
To further characterize the requirement for Stat3 in
MCF10A-Ras cells, we utilized a Matrigel assay to
examine growth in three-dimensions (3-D). The culture
of MCF10A mammary epithelial cells on a defined
basement membrane (Matrigel) results in the formation
of polarized, hollow acini which recapitulates several
aspects of glandular architecture in vivo [27]. Further-
more, oncogenes introduced into MCF10A cells disrupt
this ordered process and elicit distinct morphological
phenotypes [27]. MCF10A-Ras cells grew as amorphous
structures which were not hollow and expressed high
levels of pStat3 as determined by immunofluorescence
(Figure 4a). MCF10A cells were also plated in matrigel
revealing hollow acini which were negative for pStat3 by
immunocytochemistry (Figure 4a). Inhibition of IL-6 sig-
naling using an anti-IL6 blocking antibody or using a
pan-Jak inhibitor (P6) led to a reduction in pStat3 levels
(Figure 4a). Matrigel is a mixture of extracellular matrix
(ECM) proteins composed primarily of laminin and col-
lagen. We tested the role of matrigel and its compo-
nents for the ability to enhance Stat3 phosphorylation
and determined that matrigel and laminin were capable
of inducing pStat3 (Supplemental figure S1 in Addi-
tional file 1). Thus, the growth of MCF10A-Ras on
defined ECM proteins can enhance Stat3 activation. A
role for Stat3 in MCF10A cell growth and acini forma-
tion was also examined. A reduction in Stat3 had no
effect on the morphology of the acini nor on growth in
2-D (Supplemental figure S2 in Additional file 2).
MCF10A-Ras cells lack E-cadherin expression which
marks organized cell-cell contacts. Stat3sh cells contin-
ued to grow as filled acini but interestingly E-Cadherin
expression was restored (Figure 4b). Similarly, treatment
of MCF10A-Ras cells with inhibitors of IL-6/Jak/pStat3
signaling led to the expression of E-cadherin. Treatment
of MCF10A-Ras 3-D structures with a pan-Jak inhibitor
did not lead to a hollowing out of the structures despite
the reappearance of E-Cadherin (Supplemental figure S3
in Additional file 3). IL-6/Stat3 signaling has been
shown to inhibit E-Cadherin expression in models of
prostate and breast cancer [38,39]. This data suggest
that phosphorylated Stat3 has a role in regulating Cad-
herin expression and the loss of a requirement for cell-
cell contacts in transformed cells.
IL-6 is required for tumorigenesis of Ras transformed
MCF10A cells
To investigate the relationship between cell transforma-
tion and IL-6 signaling, we introduced an shRNA con-
struct targeting the IL-6 mRNA transcript into Ras
transformed MCF10A cells. IL-6 shRNA functionality
was confirmed using semi-quantitative RT-PCR analysis
on cells stimulated with TNF-a,al i g a n dk n o w nt o
induce IL-6 mRNA production (Figure 5a). IL-6 tran-
script levels were significantly reduced in the IL-6
shRNA expressing cells. Total Stat3, pStat3 and Ras
levels were unchanged by the loss of IL-6 (Figure 5b).
However, the addition of exogenous IL-6 led to robust
Figure 3 Exogenous IL-6 enhances pStat3 levels, binding
activity and cell migration in MCF10A-Ras cells. (a) Extracts from
MCF10A-Ras cells (C) and MCF10A-Ras treated with IL-6 (10ng/ml)
for one hour (IL-6) were analyzed by Western blot analysis for
pStat3, Stat3 and Tubulin (b) Human IL-6 mRNA levels from
MCF10A-Ras cells (C) and MCF10A-Ras cells treated with IL-6 for four
hours (IL-6) were determined by RT-PCR and normalized to b-Actin.
(c) EMSA was performed with nuclear extracts from the cell lines
described in a. Stat3 DNA binding was supershifted with anti-Stat3
antibody (IL6+Ab). (d) MCF10A-Ras cells (C) or Stat3 shRNA (S3sh)
were plated into Boyden chambers and cell migration was
determined in the absence or presence of IL-6 (C+IL6, S3Sh+IL-6)
with crystal violet staining after 24 hrs. Results are expressed as
cells/field (mean ± SD of triplicates from three independent
experiments).
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MCF10A-Ras cells expressing either control shRNA or
the IL-6 shRNA grew at similar rates when grown on
plastic (2-D) (Figure 5c). Furthermore, the chronic
administration of IL-6 to MCF10A-Ras cells did not
increase their proliferation in 2-D (Figure 5c). We exam-
ined the loss of IL-6 on cell migration and determined
that MCF10A-Ras IL-6Sh cells (IL6Sh) did not migrate
as well as control cells but the addition of IL-6 could
restore cell migration (Figure 5d). Tumorgenicity was
also assessed. MCF10A-Ras (C) cells were injected into
the flanks of nu/nu athymic mice and tumors grew as
expected (>0.4 cm3), while IL-6 shRNA expressing cells
failed to form tumors, further implicating IL-6 signaling
as a key pathway in Ras-mediated transformation
(Figure 5e).
Figure 4 3-D morphogenic assays of MCF10A-Ras cells display
IL-6/Jak/pStat3 signaling which regulate E-Cadherin levels. (a)
MCF10A cells were grown in Matrigel as were MCF10A-Ras cells
which were stained for pStat3 and Dapi by immunofluorescence
treated with DMSO control (Ras-C), P6 (a pan-Jak inhibitor) or a
blocking antibody to IL-6 (a-IL-6). (b) MCF10A-Ras cells expressing
control (HRas-C) or Stat3 shRNA (S3sh) were grown in Matrigel and
stained with Dapi and E-Cadherin (D/E-Cad) by
immunofluorescence. (c) MCF10A-Ras cells were grown in matrigel
and treated with DMSO (HRas-C), P6 or a blocking antibody to IL-6
(a-IL-6) and stained for Dapi and E-Cadherin (D/E-Cad).
Figure 5 IL-6 is required for tumorigenesis of Ras transformed
MCF10A cells. (a) Ras transformed MCF10A cells expressing control
(C) or IL-6 shRNA (IL-6sh) were stimulated with TNF-a and analyzed
for levels of IL-6 and normalized to actin by RT-PCR. (b) Extracts
from MCF10A-Ras (RasC) and MCF10AIL6Sh (RasIL6sh) were analyzed
for Stat3, pStat3, Ras and Tubulin levels. (c) MCF10A-Ras (RasC) and
MCF10AIL6Sh (RasIL6Sh) cells were plated in six-well dishes and cell
numbers were determined daily for seven days. Additionally, RasC
cells were treated with IL-6 (10 ng/ml) (Ras+IL6) daily and cell
numbers were determined. Each data point represents the mean
value from triplicate wells. (d) MCF10A-Ras (C) and MCF10AIL6Sh
(IL6Sh) cells were plated into Boyden chambers and cell migration
was determined in the absence or presence of IL-6 (C+IL6, S3Sh+IL-
6) with crystal violet staining after 24 hrs. Results are expressed as
cells/field (mean ± SD of triplicates from three independent
experiments). (e) Tumor growth in nude mice using MCF10A-Ras
cells expressing control (C) or IL-6 shRNA (IL-6sh) was determined
(mean ± SD from five independent injections).
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cells affects IL-6 production and the phosphorylation
status of Stat3
O u rd a t ai n d i c a t et h a tM C F 10A-Ras cells when grown
in two dimensions (2-D) do not express detectable levels
of pStat3 (Figure 1a). However, when these same cells
were grown in three dimensions (3-D), either in a
Matrigel assay or as tumors in nude mice, we observed
high levels of pStat3 (Figures 2 and 4). We then asked
whether the presence of pStat3 observed in 3-D growth
was reversible upon culturing in 2-D. MCF10A-Ras
tumors were surgically removed, and the epithelial cell
population was serially cultured over four days. Protein
extracts and RNA was isolated from the initial tumor
growth, as well as from each passage of these cells.
Additionally, the supernatant from the cultured cells of
each passage was obtained in order to measure IL-6
levels. MCF10A-Ras tumors exhibited high levels of
pStat3, however the passaging of these cells over time
resulted in decreased pStat3 levels (Figure 6a). The
decrease in pStat3 by Western blot correlated directly
with a decrease in IL-6 protein levels in the cultured
cell supernatants as determined by ELISA (Figure 6b)
and of IL-6 mRNA levels by real-time PCR (Figure 6c).
Conversely, we observed an increase in E-Cadherin
levels as pStat3 and IL-6 levels were decreasing (Figure
6a). Similar results were obtained from MMTV-K-Ras
tumors cultured as described above, whereby pStat3 and
IL-6 levels were markedly decreased upon two passages
(data not shown). Hence, the growth environment
(growth in 2-D versus 3-D), markedly affects the IL-6/
Jak/Stat3 signaling pathway in Ras transformed mam-
mary epithelial cells.
Discussion
We sought to determine the role of non-tyrosine phos-
phorylated Stat3 in tumorigenesis by examining the
breast epithelial cell line MCF10A cells transformed
with the H-RasV12 oncogene. Non-tyrosine phosphory-
lated Stat3 can function as a transcription factor in asso-
ciation with NF-kB driving expression of a number of
genes involved in tumorigenesis including BCL2A1, Rho
GAP6, MRAS, MET, RANTES and Cyclin B1 [11]. We
examined and compared levels of these transcripts in
MCF10A-Ras cells either expressing or lacking Stat3
and found no significant differences (data not shown).
Furthermore, we performed gene expression profiling on
these RNA populations and found only 10 transcripts
that were potentially differentially regulated as a func-
tion of non-tyrosine phosphorylated Stat3 (data not
shown). Thus in this cell line, it does not appear that
non-tyrosine phosphorylated Stat3 plays a significant
role in regulating transcription.
We examined cell proliferation and observed no differ-
ences as a function of Stat3 (Figure 1). Furthermore, sti-
mulation of cells with exogenous IL-6 led to robust Stat3
phosphorylation but did not affect cell proliferation (Fig-
ures 3 and 5c). Thus, Stat3 (either phosphorylated or
non-phosphorylated) has no significant impact on 2-D
growth. These observationsh a v ep r e v i o u s l yb e e nm a d e
demonstrating a marginal role for gp130, Stat3 or consti-
tutively activated Stat3 (Stat3-C) in 2-D cell proliferation
but a dominant one for in vivo growth [40,41]. In con-
trast to cell proliferation, we determined that Stat3 was
required for migration and invasion (Figure 1). It was
Figure 6 Growth of MCF10A-Ras cells in two- versus three-
dimensions alters the expression levels of pStat3, IL-6 and E-
Cadherin. (a) Tumors arising from immunocompromised mice
injected with MCF10A-Ras cells were cultured and passaged four
times on tissue culture plates. Extracts were isolated from an
MCF10A-Ras primary tumor (Tu) and cultured cells following serial
passage (P1, P2, P3 and P4) and analyzed for pStat3, Stat3, E-
Cadherin and Tubulin by Western blot. Quantitative evaluation of
pStat3/Stat3 (grey bars) and pStat3/Tubulin (black bars)
immunoblots by densitometry. Results are representative of three
individual experiments. Statistical significance is indicated with
asterisks (*, P < 0.05; **, P < 0.01). (b) IL-6 levels by of supernatants
from passaged cells were determined by ELISA. C. RNA from
passaged cells (P1, P2, P3, P4) was analyzed for human IL-6 mRNA
levels by real time RT-PCR (Q-PCR). Results shown are IL-6
expression normalized to HPRT from triplicates.
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IL-6 expression and gp130/Jak/Stat3 activation leading to
gp130 dependent cell migration [42]. Activated Stat3 has
been shown to mediate migration of cancer cells by regu-
lating genes such as integrin b6, tenascinC, twist and liv1
[39,43-46]. In addition to its transcriptional activating
function, phosphorylated Stat3 was shown to interact
with focal adhesion kinase (FAK) and was shown to play
ar o l ei nc e l lm i g r a t i o n[ 1 0 , 4 7 ] .W eh y p o t h e s i z et h a t
migrating or invading Ras transformed MCF10A cells
activate Rac1 which leads to increased IL-6 expression,
Stat3 tyrosine phosphorylation and enhanced cell migra-
tion and invasion. This process can be enhanced by para-
crine IL-6 and partially inhibited by reducing IL-6 levels
(Figure 5).
IL-6 was shown to be expressed to high levels in
numerous Ras-expressing cell lines including kidney,
fibroblasts, human mammary epithelial cells and pan-
creatic cancer derived cell lines when grown in 2-D
[23]. In contrast, we do not see any appreciable IL-6
mRNA or protein expression in Ras transformed
MCF10A cells grown in 2-D (Figures 3b and 5a). Per-
haps, expression levels of Ras influence IL-6 production
which may have been lower in our cells than in those
described by the Counter laboratory. In contrast to cells
grown on plastic, we observed that MCF10A-Ras cells
grown in 3-D either in basement membrane (Matrigel)
cultures or as xenografts expressed high levels of IL-6
and pStat3 (Figures 2, 4 and Supplemental figure S1 in
Additional file 1). In addition, MMTV-Ras transgenic
mice also developed tumors expressing IL-6 and pStat3
(Figure 2). Thus, our data suggest that the environment
in which Ras transformed cells are grown can regulate
the expression levels of IL-6.
MCF10A cells are immortalized human mammary
epithelial cells that undergo a program of apical-basolat-
eral polarization, proliferation, growth arrest and apop-
tosis leading to acinar formation when grown in
matrigel [48-50]. These 3-D cultures are felt to be a
more relevant system to examine cell growth, cell adhe-
sion and cell-ECM interactions recapitulating some of
architectural changes observed in vivo [49]. Expression
of activated H-Ras in MCF10A cells led to changes in
the morphology of these structures from organized hol-
low acini to solid irregularly shaped structures lacking
E-Cadherin expression (Figure 4) [51]. We previously
demonstrated that prostate epithelial cells expressing a
constitutively activated Stat3 (Stat3-C) had decreased
E-Cadherin levels [39]. Furthermore, IL-6 stimulated
mammary epithelial cells downregulate E-Cadherin
expression [38]. Here we provide further evidence that
pStat3 negatively regulates E-Cadherin expression in Ras
transformed MCF-10A cells as inhibiting its activity led
to an increase in E-Cadherin expression (Figures 4 and
6). Although Jak inhibition restored E-Cadherin expres-
sion in MCF10A-Ras cells we did not observe any hol-
lowing out of the acini suggesting that E-Cadherin
expression is insufficient to induce a reorganization of
the acini or induce apoptosis of the centrally located
cells (Figure 4 and Supplemental figure S3 in Additional
file 3). Although Jak inhibition had no affect on the 2-D
growth of MCF10A-Ras cells we did see a loss of viabi-
lity in the acinar structures grown in 3-D over a seven-
day period (data not shown). These observations further
support the hypothesis that inhibition of IL-6/Jak/Stat3
signaling inhibits 3-D growth and tumorigenesis but not
2-D growth.
The mechanisms of IL-6 transcriptional regulation in
transformed cells involves the activation and recruit-
ment to the IL-6 promoter of a number of transcription
factors including AP-1, NF-kB, (NF-IL6) or C/EBPb and
CREB [52,53]. Furthermore, a myriad of other transcrip-
tion factors in association with the above mentioned
proteins can modulate expression of the IL-6 gene for
example nuclear hormone receptors (GR and ER),
PPARg and Stat3 [12,54-60]. IL-6 mRNA stability is
also tightly regulated through the association of RNA-
b i n d i n gp r o t e i n s( A U F 1 )w i t ht h e3 ’UTR and activation
of p38 [61,62]. We examined levels of activated NF-kB,
AP-1, CREB and C/EBPb in MCF10A-Ras cells (grown
in 2-D culture) by EMSA and did not observe any bind-
ing of these factors suggesting that Ras expression in
MCF10A cells is insufficient to mediate activation of the
IL-6 gene (data not shown). Furthermore, our data sug-
gest that in order for Ras transformed cells to produce
high levels of IL-6, cells need to be exposed to extracel-
lular matrix proteins such ast h o s ef o u n di nm a t r i g e l
(principally laminin) or to an in vivo environment which
exposes epithelial cells to extracellular matrix proteins
but also fibroblasts, endothelial cells and macrophages
which produce growth factors capable of mediating IL-6
expression. When MCF10A-Ras cells were cultured on
plates coated with matrigel, collagen I, collagen IV,
fibronectin and laminin we found that matrigel and
laminin could induce modest expression of pStat3 (Sup-
plemental figure S1 in Additional file 1). We suggest
that integrin engagement of ECM proteins can enhance
pStat3 through upregulation of IL-6. Indeed, there are
examples whereby integrin engagement with extracellu-
lar matrix proteins such as collagen and laminin leads
to increased IL-6 production [63-65]. The work by the
Bissell laboratory has demonstrated that the nature of
the ECM matrix (solid or gel-like) can profoundly influ-
ence cell morphology and gene expression [66]. Further-
more, stromal cells surrounding epithelial cells secrete
IL-6 and in a paracrine manner can induce epithelial
cells to produce IL-6 in an autocrine manner [37,67].
Since murine IL-6 does not engage the human IL-6R,
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human IL-6 expression and Stat3 phosphorylation in
these tumors [68]. For example, aberrant EGFR signaling
in glioblastoma, lung cancer and MCF10A cells led to
enhanced IL-6 production and signaling [32,69].
In order to determine whether the 3-D environment
is required for sustained IL-6 expression by epithelial
cells we cultured tumor cells (either from MCF10A-
R a sx e n o g r a f t so rM M T V - R a st u m o r s )a n dp a s s a g e d
them on plastic dishes (2-D environment). After a few
passages in culture, we have an enriched epithelial cell
population (devoid of fibroblasts, endothelial cells and
immune cells) which no longer expresses IL-6 nor
pStat3 (Figure 6). These data suggest that the micro-
environment (including stromal cells, endothelial cells
and immune cells) is critical for the expression of
the IL-6 ligand which results in activation of Stat3. A
requirement for IL-6 signaling in tumor formation
has been demonstrated by using IL-6 knock-down
approaches as well as blocking antibodies to IL-6 in a
variety of cell types [23,32,70,71]. Here we also demon-
strate a requirement for IL-6 in MCF10A-Ras mediated
tumor formation with no apparent effect on 2-D
growth.
Conclusions
There is increasing evidence that tumorigenesis and
metastatic progression is dependent on the interactions
between tumor cells and the context in which they are
grown: the tumor microenvironment. Our data demon-
strate cross-talk between the Ras oncogene and the
IL-6/Stat3 signaling pathway through up-regulation of
IL-6 as a function of the cellular context.
Additional material
Additional file 1: Supplemental figure S1. ECM induces Stat3
phosphorylation. Extracts from MCF10A-Ras cells plated on plastic (C)),
plastic coated Matrigel (M), plastic (C), Collagen I (CI), Collagen V(CV),
Fibronectin (F) and Laminin (LA) for 16 hours and were analyzed for
pStat3 and Tubulin levels.
Additional file 2: Supplemental figure S2. Stat3 has no effect on
acinar formation or cell growth in MCF10A cells. A. Extracts from
MCF10A cells expressing control (C) or Stat3 shRNA (S3sh) were analyzed
for levels of Stat3, tyrosine phosphorylated (pStat3) and Tubulin by
Western blot analysis. B. MCF10A cells (Control) or MCF10A Stat3Sh
(S3Sh) were grown on Matrigel and form hollowed structures which
were stained for pStat3 (green) and Dapi (blue) by immunofluorescence.
C. MCF10A cells expressing control (C) or Stat3 shRNA (S3sh) were plated
in six-well dishes and cell numbers were determined daily for seven
days. Each data point represents the mean value from triplicate wells.
Additional file 3: Supplemental figure S3. Jak inhibition does not
alter the morphology of MCF10A-Ras cells in Matrigel. MCF10A-Ras
cells were grown on Matrigel and structures were stained for Dapi by
immunofluorescence treated with DMSO control (Ras-C) or P6 (a pan-Jak
inhibitor) for one week.
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